Skip to main content

Table 3 Clinical severity scores and co-morbidity rates in hospitalised patients with severe and non-severe COVID-19

From: Clinical and laboratory characteristics of patients hospitalised with COVID-19: clinical outcomes in Abu Dhabi, United Arab Emirates

  Overall
N = 9390
Severe
N = 721
Non-severe
N = 8669
P-value
MEWS
Median (IQR)
0 (0–0) 4 (2–6) 0 (0–0)  < 0.0001
SOFA score
Median (IQR)
0 (0–0) 0 (0–3) 0 (0–0)  < 0.0001
Glasgow Coma Scale
Median (IQR)
14.9 (3–15) 15 (15–15) 15 (15–15)  < 0.0001
Co-morbiditiesa 2706 (28.8%) 542 (75.17%) 2164 (24.93%)  
 Diabetes mellitus 962 (10.24%) 195 (27.05%) 767 (8.85%)  < 0.0001
 Hypertension 1028 (10.94%) 237 (32.87%) 791 (9.12%)  < 0.0001
 COPD 3 (0.03%) 1 (0.14%) 2 (0.02%) 0.095
 Asthma 176 (1.87%) 16 (2.22%) 160 (1.85%) 0.477
 CAD 89 (0.95%) 16 (2.22%) 73 (0.84%) 0.0002
 Ischaemic heart disease 93 (0.99%) 9 (1.25%) 84 (0.97%) 0.466
 CKD 166 (1.76%) 41 (5.69%) 125 (1.44%)  < 0.0001
 Malignancy 189 (2.01%) 27 (3.74%) 162 (2.40%) 0.0005
 Pregnancy 40 (0.43%) 4 (0.5%) 36 (0.4%) 0.580
 Body mass index
Median (IQR)
26.22 (23.83–29.34) 25.99 (23.88–29.48) 26.23 (23.83–29.29) 0.589
  1. aPresence of one or more co-morbidity